Fidasimtamab, designated DLTV – 1504, represents the innovative approach in the battle against multiple myeloma. The drug is a dual-specific agent designed to concurrently engage CD3-positive T cells https://fidasimtamab-recombinant718081.blogdigy.com/fidasimtamab-this-promising-treatment-in-advanced-myeloma-treatment-68850157